Bioasis Technologies Inc. BIOAF

Full chart Compare

Set alert

0.00 USD 0.00 (+0.00%)

At closeNov 10, 2026, 4:00 PM EST

0.0001 Day range 0.0001

0.0001 52-week range 0.0002

YTD: -50.00%
1 year: -50.00%

News

6 months ago defenseworld.net Financial Analysis: Prelude Therapeutics (NASDAQ:PRLD) versus Bioasis Technologies (OTCMKTS:BIOAF) Prelude Therapeutics (NASDAQ: PRLD - Get Free Report) and Bioasis Technologies (OTCMKTS:BIOAF - Get Free Report) are both medical companies, but which is the superior business? We will compare the…
5 years ago globenewswire.com Bioasis to Attend Upcoming Industry Conferences NEW HAVEN, Conn., Sept. 30, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™…
5 years ago globenewswire.com Bioasis Technologies Inc. Announces the Appointment of Shadow Lake Group as Business Development Advisor NEW HAVEN, Conn., Aug. 18, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company…
5 years ago globenewswire.com Bioasis Announces Allowance of Japanese Patent Application in Japan Relating to xB³™ Fusion Protein Comprising Iduronate-2-sulfatase NEW HAVEN, Conn., Aug. 09, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company…
5 years ago globenewswire.com Bioasis Announces Filing of Its First Quarter Financial Statements and MD&A NEW HAVEN, Conn., July 29, 2021 (GLOBE NEWSWIRE) -- Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company…
5 years ago globenewswire.com Bioasis Technologies Inc. Announces Stock Option Grants, Jeffrey Sprouse Appointed Preclinical Program Manager NEW HAVEN, Conn., July 20, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company…
5 years ago proactiveinvestors.com Bioasis Technologies reports positive results from an efficacy study of its blood-brain barrier penetrant Bioasis Technologies Inc (CVE:BTI) (OTCQB:BIOAF) said results from an efficacy study of a blood-brain barrier penetrant interleukin-1 receptor inhibitor were successful in a preclinical rodent model…
5 years ago globenewswire.com Bioasis Announces Positive Results From an Efficacy Study of xB3™-IL-1RA in a Model of Multiple Sclerosis NEW HAVEN, Conn., July 07, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company…
5 years ago proactiveinvestors.com Bioasis Technologies appoints former PricewaterhouseCoopers veteran Dave Jenkins as CFO Bioasis Technologies Inc (CVE:BTI) (OTCQB:BIOAF) has announced the appointment of Dave Jenkins as chief financial officer. Jenkins has more than 35 years of experience in accounting and finance…
5 years ago globenewswire.com Bioasis Announces the Appointment of Dave Jenkins as Chief Financial Officer NEW HAVEN, Conn., July 01, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company…
5 years ago proactiveinvestors.com Bioasis Technologies partners with Oxyrane to evaluate combining brain therapy technologies Bioasis Technologies Inc (CVE:BTI) (OTCQB:BIOAF) reports that it will enter a research collaboration with Oxyrane UK Ltd. The Guilford, Connecticut-based Bioasis is a pre-clinical, research-stage…
5 years ago globenewswire.com Bioasis Technologies Inc. and Oxyrane UK Ltd. enter into a Research Collaboration NEW HAVEN, Conn. and MANCHESTER, United Kingdom, June 30, 2021 (GLOBE NEWSWIRE) -- Bioasis Technologies Inc. (TSXV:BTI; OTCQB:BIOAF) (“Bioasis”) and Oxyrane UK Ltd. (“Oxyrane”) are pleased to…
5 years ago globenewswire.com Bioasis Technologies Announces Closing of Initial C$3,000,000 Funding by Lind Partners NEW HAVEN, Conn., June 29, 2021 (GLOBE NEWSWIRE) -- Bioasis Technologies Inc. (“Bioasis” or the “Company”) (TSX.V:BTI; OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company…
5 years ago globenewswire.com Bioasis Announces Filing of Its Fourth Quarter and Fiscal Year-End Financial Statements and MD&A NEW HAVEN, Conn., June 25, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company…
5 years ago proactiveinvestors.com Bioasis strikes convertible security funding agreement for institutional investment of up to C$10M Bioasis Technologies Inc (CVE:BTI) (OTCQB:BIOAF) (FRA:107) said that it has struck a convertible security funding agreement with Lind Global Macro Fund LP, an entity managed by the New York-based…
5 years ago globenewswire.com Bioasis Technologies enters into Convertible Security Funding Agreement for Institutional Investment of up to C$10 million NEW HAVEN, Conn., June 22, 2021 (GLOBE NEWSWIRE) -- Bioasis Technologies Inc. (“Bioasis” or the “Company”) (TSX.V:BTI; OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company…
5 years ago proactiveinvestors.com Bioasis has the best platform technology for shuttling drugs across the blood-brain barrier Platform licensed to Chiesi for developing drugs Will receive $3 million upfront, and as much as $138 million in additional milestones and undisclosed royalties Has inhouse development programs…
5 years ago proactiveinvestors.com Bioasis Technologies announces publication validating its xB3 platform to cross the intact blood-brain barrier Bioasis Technologies Inc (CVE:BTI) (OTCQB:BIOAF) has announced the publication of research validating the ability of its xB3 platform to cross the intact blood-brain barrier (BBB) and its…
5 years ago globenewswire.com Bioasis Announces Publication Validating its xB³ ™ Platform Technology for CNS Therapeutics NEW HAVEN, Conn., June 03, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company…
5 years ago proactiveinvestors.com Bioasis Technologies teams up with Aposense for siRNA delivery research Bioasis Technologies Inc (CVE:BTI) (OTCQB:BIOAF) announced it has formed a research collaboration with Aposense Limited, an Israeli bio-pharmaceutical company specializing in development of novel…
7 years ago benzinga.com Stocks That Fell Through 52-Week Lows Wednesday